172 related articles for article (PubMed ID: 11382373)
1. New heparin dosing recommendations for patients with acute coronary syndromes.
Menon V; Berkowitz SD; Antman EM; Fuchs RM; Hochman JS
Am J Med; 2001 Jun; 110(8):641-50. PubMed ID: 11382373
[TBL] [Abstract][Full Text] [Related]
2. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes.
Alexander KP; Chen AY; Roe MT; Newby LK; Gibson CM; Allen-LaPointe NM; Pollack C; Gibler WB; Ohman EM; Peterson ED;
JAMA; 2005 Dec; 294(24):3108-16. PubMed ID: 16380591
[TBL] [Abstract][Full Text] [Related]
3. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
Cohen M
J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
[TBL] [Abstract][Full Text] [Related]
4. A new regimen for heparin use in acute coronary syndromes.
Hochman JS; Wali AU; Gavrila D; Sim MJ; Malhotra S; Palazzo AM; De La Fuente B
Am Heart J; 1999 Aug; 138(2 Pt 1):313-8. PubMed ID: 10426845
[TBL] [Abstract][Full Text] [Related]
5. 2007 Guideline update for unstable angina/non-ST-segment elevation myocardial infarction: focus on antiplatelet and anticoagulant therapies.
Coons JC; Battistone S
Ann Pharmacother; 2008 Jul; 42(7):989-1001. PubMed ID: 18577763
[TBL] [Abstract][Full Text] [Related]
6. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study.
Théroux P; Alexander J; Pharand C; Barr E; Snapinn S; Ghannam AF; Sax FL
Circulation; 2000 Nov; 102(20):2466-72. PubMed ID: 11076818
[TBL] [Abstract][Full Text] [Related]
7. Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
Lauer MA; Houghtaling PL; Peterson JG; Granger CB; Bhatt DL; Sapp SK; Simoons ML; Harrington RA; Topol EJ; Lincoff AM;
Circulation; 2001 Dec; 104(23):2772-7. PubMed ID: 11733393
[TBL] [Abstract][Full Text] [Related]
8. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage.
Giugliano RP; McCabe CH; Antman EM; Cannon CP; Van de Werf F; Wilcox RG; Braunwald E;
Am Heart J; 2001 May; 141(5):742-50. PubMed ID: 11320361
[TBL] [Abstract][Full Text] [Related]
9. Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction.
Bosch X; Marrugat J
Cochrane Database Syst Rev; 2001; (4):CD002130. PubMed ID: 11687143
[TBL] [Abstract][Full Text] [Related]
10. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial.
Valgimigli M; Frigoli E; Leonardi S; Vranckx P; Rothenbühler M; Tebaldi M; Varbella F; Calabrò P; Garducci S; Rubartelli P; Briguori C; Andó G; Ferrario M; Limbruno U; Garbo R; Sganzerla P; Russo F; Nazzaro M; Lupi A; Cortese B; Ausiello A; Ierna S; Esposito G; Ferrante G; Santarelli A; Sardella G; de Cesare N; Tosi P; van 't Hof A; Omerovic E; Brugaletta S; Windecker S; Heg D; Jüni P;
Lancet; 2018 Sep; 392(10150):835-848. PubMed ID: 30153988
[TBL] [Abstract][Full Text] [Related]
11. Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators.
Becker RC; Cannon CP; Tracy RP; Thompson B; Bovill EG; Desvigne-Nickens P; Randall AM; Knatternud G; Braunwald E
Am Heart J; 1996 Mar; 131(3):421-33. PubMed ID: 8604620
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators
N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103
[TBL] [Abstract][Full Text] [Related]
13. Antiplatelet intervention in acute coronary syndrome.
Arora RR; Rai F
Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
[TBL] [Abstract][Full Text] [Related]
14. New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines.
Spinler SA; Hilleman DE; Cheng JW; Howard PA; Mauro VF; Lopez LM; Munger MA; Gardner SF; Nappi JM
Ann Pharmacother; 2001 May; 35(5):589-617. PubMed ID: 11346067
[TBL] [Abstract][Full Text] [Related]
15. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
[TBL] [Abstract][Full Text] [Related]
16. Higher Maximum Doses and Infusion Rates Compared with Standard Unfractionated Heparin Therapy Are Associated with Adequate Anticoagulation without Increased Bleeding in Both Obese and Nonobese Patients with Cardiovascular Indications.
Floroff CK; Palm NM; Steinberg DH; Powers ER; Wiggins BS
Pharmacotherapy; 2017 Apr; 37(4):393-400. PubMed ID: 28107569
[TBL] [Abstract][Full Text] [Related]
17. Improved in-hospital outcomes in acute coronary syndromes (unstable angina/non-ST segment elevation myocardial infarction) despite similar TIMI risk scores.
Almeda FQ; Hendel RC; Nathan S; Meyer PM; Calvin JE; Klein LW
J Invasive Cardiol; 2003 Sep; 15(9):502-6. PubMed ID: 12947210
[TBL] [Abstract][Full Text] [Related]
18. Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction.
Cheng S; Morrow DA; Sloan S; Antman EM; Sabatine MS
Circulation; 2009 Mar; 119(9):1195-202. PubMed ID: 19237657
[TBL] [Abstract][Full Text] [Related]
19. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction.
Antman EM; McCabe CH; Braunwald E
Am Heart J; 2002 Feb; 143(2):229-34. PubMed ID: 11835024
[TBL] [Abstract][Full Text] [Related]
20. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide.
Goodman SG; Fitchett D; Armstrong PW; Tan M; Langer A;
Circulation; 2003 Jan; 107(2):238-44. PubMed ID: 12538422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
